
FIGO 2023 Upstaging: Overtreatment or Overdue Precision?
Sep 1, 2026 - 31:57
Radio and PodcastLive Radio & Podcasts
Editor's Choice: Biomarker heterogeneity and efficacy of durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory...